Pharmacogenomic Profile of Soy Isoflavone Concentrate in the Prostate of Nrf2 Deficient and Wild-Type Mice
Avantika Barve
Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorTin Oo Khor
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorSujit Nair
Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorWen Lin
Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorSiwang Yu
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorMohit Raja Jain
Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07013
Search for more papers by this authorJefferson Y. Chan
Department of Pathology, University of California, D440 Medical Sciences, Irvine, California 92697
Search for more papers by this authorCorresponding Author
Ah-Ng Kong
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854 Telephone: 732-445-3831 ext. 228; Fax: 732-445-3134Search for more papers by this authorAvantika Barve
Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorTin Oo Khor
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorSujit Nair
Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorWen Lin
Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorSiwang Yu
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Search for more papers by this authorMohit Raja Jain
Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07013
Search for more papers by this authorJefferson Y. Chan
Department of Pathology, University of California, D440 Medical Sciences, Irvine, California 92697
Search for more papers by this authorCorresponding Author
Ah-Ng Kong
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854 Telephone: 732-445-3831 ext. 228; Fax: 732-445-3134Search for more papers by this authorAbstract
The involvement of Nrf2—a bZip transcription factor in soy isoflavones induced protection against oxidative stress and cancer has been reported. To gain better insight into the role of Nrf2 in prostate cancer chemoprevention by soy isoflavones, we examined the pharmacogenomics and gene expression profiles elicited by soy isoflavones in the prostates of C57BL/6J/Nrf2(−/−) and C57BL6J/Nrf2(+/+) wildtype. The profiles were analyzed using 45000 Affymetrix mouse genome 430-2.0 array and Genespring-7.2 software. The results obtained from microarray were further validated by real-time reverse transcription-PCR. Clusters of genes that were induced or suppressed more than twofold were identified as Nrf2 regulated soy isoflavone induced or suppressed genes. Classification based on their biological function revealed that genes mainly belonging to the categories of electron transport, phase II metabolizing enzymes, cell growth and differentiation, apoptosis, cell cycle, transcription factors, transport, mRNA processing, and carbohydrate homeostasis were either induced or suppressed by soy isoflavone and regulated by Nrf2. In addition, modulation of novel target genes such as LATS2 and GREB1 were identified to be mediated by Nrf2. Thus our current study provides a potential link between cancer chemopreventive properties of soy derived phytochemicals, the transcription factor Nrf2 and prevention of prostate cancer. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:4528–4545, 2008
REFERENCES
- 1 deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B. 2004. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 63: 259–263.
- 2 Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313–322.
- 3 Chen C, Kong AN. 2004. Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic Biol Med 36: 1505–1516.
- 4 Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. 2005. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14: 590–595.
- 5 Gao J, Arnold JT, Isaacs JT. 2001. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61: 5038–5044.
- 6 Adlercreutz H. 1995. Phytoestrogens: Epidemiology and a possible role in cancer protection. Environ Health Perspect 103: 103–112.
- 7 Weber KS, Setchell KD, Stocco DM, Lephart ED. 2001. Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5alpha-reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague-Dawley rats. J Endocrinol 170: 591–599.
- 8 Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS. 2005. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 11: 7033–7041.
- 9 Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. 2005. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 135: 989–995.
- 10 Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. 2001. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61: 6777–6782.
- 11 Wang J, Eltoum IE, Lamartiniere CA. 2004. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol Cell Endocrinol 219: 171–180.
- 12 Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. 2003. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47: 111–117.
- 13 Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Crowell J, Paglieri J, Zeisel SH. 2003. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77: 875–882.
- 14 Raschke M, Rowland IR, Magee PJ, Pool-Zobel BL. 2006. Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress. Carcinogenesis 27: 2322–2330.
- 15 Chung MJ, Kang AY, Lee KM, Oh E, Jun HJ, Kim SY, Auh JH, Moon TW, Lee SJ, Park KH. 2006. Water-soluble genistin glycoside isoflavones up-regulate antioxidant metallothionein expression and scavenge free radicals. J Agric Food Chem 54: 3819–3826.
- 16 Mahn K, Borras C, Knock GA, Taylor P, Khan IY, Sugden D, Poston L, Ward JP, Sharpe RM, Vina J, Aaronson PI, Mann GE. 2005. Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J 19: 1755–1757.
- 17 Shen G, Xu C, Hu R, Jain MR, Gopalkrishnan A, Nair S, Huang MT, Chan JY, Kong AN. 2006. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol Cancer Ther 5: 39–51.
- 18 McVey MJ, Cooke GM, Curran IH. 2004. Altered testicular microsomal steroidogenic enzyme activities in rats with lifetime exposure to soy isoflavones. J Steroid Biochem Mol Biol 92: 435–446.
- 19 Sporn MB, Dunlop NM, Newton DL, Smith JM. 1976. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35: 1332–1338.
- 20 Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, Lin W, Reddy B, Chan JY, Kong AN. 2006. Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci 79: 1944–1955.
- 21 Slitt AL, Cherrington NJ, Dieter MZ, Aleksunes LM, Scheffer GL, Huang W, Moore DD, Klaassen CD. 2006. trans-Stilbene oxide induces expression of genes involved in metabolism and transport in mouse liver via CAR and Nrf2 transcription factors. Mol Pharmacol 69: 1554–1563.
- 22 Laurenzana EM, Weis CC, Bryant CW, Newbold R, Delclos KB. 2002. Effect of dietary administration of genistein, nonylphenol or ethinyl estradiol on hepatic testosterone metabolism, cytochrome P-450 enzymes, and estrogen receptor alpha expression. Food Chem Toxicol 40: 53–63.
- 23 Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, Lin W, Reddy B, Chan JY, Kong AN. 2006. Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (−/−) mice. Cancer Lett 243: 170–192.
- 24 Nair S, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, Jain MR, Liew C, Chan JY, Kong AN. 2007. Toxicogenomics of endoplasmic reticulum stress inducer tunicamycin in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Toxicol Lett 168: 21–39.
- 25 Nair S, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, Jain MR, Lin W, Keum YS, Liew C, Chan JY, Kong AN. 2006. Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Pharm Res 23: 2621–2637.
- 26 Shen G, Xu C, Hu R, Jain MR, Nair S, Lin W, Yang CS, Chan JY, Kong AN. 2005. Comparison of (−)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (−/−) mice. Pharm Res 22: 1805–1820.
- 27 Sarkar FH, Li Y. 2002. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 21: 265–280.
- 28 Steele VE, Pereira MA, Sigman CC, Kelloff GJ. 1995. Cancer chemoprevention agent development strategies for genistein. J Nutr 125: 713S–716S.
- 29 Yu L, Blackburn GL, Zhou JR. 2003. Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J Nutr 133: 389–392.
- 30 Choi EJ, Kim T, Lee MS. 2007. Pro-apoptotic and cytotoxic effect of genistein and genistin in human ovarian cancer SK-OV-3 cells. Life Sci 80: 1403–1408.
- 31 Kwon SH, Kang MJ, Huh JS, Ha KW, Lee JR, Lee SK, Lee BS, Han IH, Lee MS, Lee MW, Lee J, Choi YW. 2007. Comparison of oral bioavailability of genistein and genistin in rats. Int J Pharm 337: 148–154.
- 32 Sergeev IN. 2004. Genistein induces Ca2+ -mediated, calpain/caspase-12-dependent apoptosis in breast cancer cells. Biochem Biophys Res Commun 321: 462–467.
- 33 Jimenez-Velasco A, Roman-Gomez J, Agirre X, Barrios M, Navarro G, Vazquez I, Prosper F, Torres A, Heiniger A. 2005. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia 19: 2347–2350.
- 34 Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA, Freedman LP, Bai C. 2004. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol 18: 2011–2023.
- 35 Meehan KL, Holland JW, Dawkins HJ. 2002. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50: 54–63.
- 36 Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME. 2006. GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate 66: 886–894.
- 37 Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E. 2006. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98: 1819–1825.
- 38 Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, Yamamoto M. 2001. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 6: 857–868.
- 39 Lin W, Shen G, Yuan X, Jain MR, Yu S, Zhang A, Chen JD, Kong AN. 2006. Regulation of Nrf2 transactivation domain activity by p160 RAC3/SRC3 and other nuclear co-regulators. J Biochem Mol Biol 39: 304–310.
- 40 Shen G, Hebbar V, Nair S, Xu C, Li W, Lin W, Keum YS, Han J, Gallo MA, Kong AN. 2004. Regulation of Nrf2 transactivation domain activity. The differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein. J Biol Chem 279: 23052–23060.
- 41 McCarty MF. 2004. Targeting multiple signaling pathways as a strategy for managing prostate cancer: Multifocal signal modulation therapy. Integr Cancer Ther 3: 349–380.
